Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

HAYWARD, Calif., June 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.The purpose of the PEARL-SC study was to identify an effective and safe dose for future phase 3 clinical studies and explore key inclusion criteria and clinical endpoints in an effort to maximize differentiation of blisibimod from currently available therapies.  The 200mg weekly subcutaneous dose of blisibimod demonstrated a strong trend in improved clinical response as early as week 16 (p= 0.14), at the primary endpoint (p=0.15) and throughout week 44 including a statistically significant improvement at week 20 versus placebo (p=0.02).

In a predefined phase 3 target population of severely ill, seropositive lupus patients, defined as SELENA-SLEDAI ≥10 and receiving background corticosteroid medication, a more pronounced effect was seen in the 200mg weekly dose group demonstrating a 13.8% treatment difference compared to placebo at 24 weeks.  In this subgroup, planned for phase 3 studies, separation of clinical response occurred as early as week 8 and was also sustained through week 44.  Results from the 200mg weekly group are presented in Table 1.

"The extensive data in the target severe population from our Phase 2 clinical program supports the initiation of a much smaller yet differentiated Phase 3 registration plan with the selected dose of blisibimod in patients with severe systemic lupus erythematosus.  We have prospectively demonstrated for the first time the possibility for a subcutaneously administered BAFF inhibitor to be used in the treatment of a severe lupus population.  The subgroup of severe pat
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
(Date:10/17/2014)...  Ameritox SM , the nation,s leader in medication ... Smith , M.D., as Chief Medical Officer. In this ... resources for healthcare providers, patients and managed care plans. ... a variety of healthcare companies that have provided him ... behavioral health sides of Ameritox,s business. He most recently ...
(Date:10/17/2014)... Oct. 17, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro® ... Healthcare Center , a 140,000 square foot, 44-bed hospital ... hospital serves a large number of Native ... Oklahoma and beyond. A portion of its ...
Breaking Medicine Technology:Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... 2014 Stephen T. Greenberg, M.D., with offices ... the 10th consecutive year as one of Long Island’s best ... also been nominated as the best provider for Botox injections. ... best Day Spa and best Laser Treatment center on Long ... readers can vote for the contest once per day, per ...
(Date:10/19/2014)... – The U.S. Government has initiated a major ... by 2025. However, a workgroup of nearly 40 ... in the U.S. Government,s National Plan to Address ... in scale, and adequately funded in order to ... by the workgroup to enlarge and strengthen the ...
(Date:10/19/2014)... One major trend in the market is ... high-cost structure leading to the implementation of more proton ... the Global Proton Therapy market to grow ... 2013-2018. According to the report, one of the main ... medical diagnostics and therapeutics. The advances in technology led ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... The American School,Health Association, the National Association of ... today joined together to create,one voice to urge ... Prevention,and Tobacco Control Act, which would give the ... three associations, each formed to assist the Nation,s ...
... representatives are invited,to a photo opportunity with the Honourable ... Governor, in light of an,international collaboration announcement on cancer ... Convention in San Diego., Who: ... Arnold Schwarzenegger, The ...
... Inc.,(Nasdaq: HOLX ) today announced that Glenn Muir, ... Annual Healthcare Conference being,held June 24 - 26, 2008, ... Interested parties are invited to listen to a ... 25, 2008, at 12:30 PM.,Eastern Time on the investor ...
... also express concern about psoriasis drug,s possible risks for ... strengthening , , WEDNESDAY, June 18 (HealthDay News) -- ... Wednesday that the psoriasis drug Enbrel be approved for ... skin disease. , The outside medical experts, in a ...
... higher annual volumes of patients with inflammatory bowel disease ... than hospitals with lower volumes of IBD patients, according ... College of Wisconsin in Milwaukee. ,The study ... for patients who undergo surgery for Crohn,s Disease, a ...
... SF-12v2 Health Survey Results are Used to Measure Physical ... and Mental Health Status of Program Participants, ... the,SilverSneakers(R) Fitness Program was created to encourage older adults ... the nation,s leading,fitness program aimed exclusively at older adults. ...
Cached Medicine News:Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 3Health News:Choice of hospital impacts outcomes for inflammatory bowel disease surgery 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 3
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... AnchorSew™ 3 mm is a resorbable repair device ... ArthroSew suturing device to attach soft tissue to ... into a prepared hole in the bone, and ... tissue anchors are made of a resorbable copolymer, ...
... is generally used when anchor size ... anchor is packaged sterile and comes ... and needles. Although pre-drilling is not ... Harpoon®, 1.6mm & 1.8mm drills are ...
Medicine Products: